Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Receivables - Net: 2020-2022

  • Mereo BioPharma Group's Receivables - Net rose 2.90% to $1.1 million in Q2 2022 from the same period last year, while for Jun 2022 it was $1.1 million, marking a year-over-year increase of 2.90%. This contributed to the annual value of $1.1 million for FY2021, which is 5.63% up from last year.
  • According to the latest figures from Q2 2022, Mereo BioPharma Group's Receivables - Net is $1.1 million, which was up 3.93% from $1.1 million recorded in Q4 2021.
  • Mereo BioPharma Group's Receivables - Net's 5-year high stood at $1.1 million during Q2 2022, with a 5-year trough of -$686,658 in Q2 2020.
  • Its 3-year average for Receivables - Net is $740,064, with a median of $1.1 million in 2021.
  • Data for Mereo BioPharma Group's Receivables - Net shows a peak YoY skyrocketed of 260.40% (in 2021) over the last 5 years.
  • Mereo BioPharma Group's Receivables - Net (Quarterly) stood at $1.1 million in 2020, then rose by 2.72% to $1.1 million in 2021, then climbed by 2.90% to $1.1 million in 2022.
  • Its last three reported values are $1.1 million in Q2 2022, $1.1 million for Q4 2021, and $1.1 million during Q2 2021.